CMD ImPACT
The CMD ImPACT project is a unique collaboration between The Royal College of Pathologists, Cancer Research UK and the ABPI Pharmaceutical Oncology Initiative (POI).
Together we share a clear ambition - to improve cancer outcomes by making sure that patients with cancer have access to the stratified medicines they need.
The CMD ImPACT project has brought together complementary expertise from the three partner organisations to improve patient outcomes by exploring how to support the delivery of stratified medicine in the NHS.
This section of The Royal College of Pathologists website is dedicated to sharing one of the unique resources developed by the project – the CMD ImPACT business planning tool.
Analyse their current diagnostics function from resource and other overhead costs to test volumes over time, test cost analysis and commercial vs. lab developed tests cost comparisons
Identify and cost areas for efficiencies and improvements in running diagnostic tests within their labs
Assist with resource planning for future tests
Produce robust business cases to support funding opportunities for new diagnostics to be commissioned
Extensive, user tested and sophisticated development
This tool is the result of extensive work, including:
The involvement and piloting by some of the leading cancer molecular diagnostics laboratories in the UK.
These labs shared all their experiences of best practice with running various diagnostics in their labs, as well as the successes and failures of previous business case applications aimed at securing commissioning support and further tests funding
Literature reviews as well as research into the current status of stratified medicine provision in the UK
Contributions from key stakeholders, including 16 different NHS organisations and 14 other key public and private sector organisations
Extensive utilisation of unique expertise held in the partner organisations (POI, CR-UK, RCPath), steering group, as well as specialist healthcare consultancy support (Concentra)
This tool allows all laboratories running cancer molecular diagnostics to analyse their operations and produce business case analysis. This is regardless of whether they are labs with a foundation in pathology, genetic diseases or from a research science heritage. The tool is also as useful for both private and NHS labs, and caters for an extensive range of different molecular diagnostics and tests – both Laboratory Developed Tests (LDTs) and commercial test kits.
This tool allows labs to easily understand and analyse how their current test operations are running, identify improvements and present new requirements for new tests. This includes analysis of diagnostics volumes, batch sizes and turnaround times of specific tests. It also allows calculating diagnostic pathway costs, test development projects, sources of income for funding, staffing considerations, and factoring in other lab overheads.
This tool was uniquely developed with intelligence from some of the UK’s leading cancer molecular diagnostics laboratories on how to successfully meet the criteria of commissioners – including CCGs and Foundation Trust finance departments - in demonstrating value and rationale to investing in further diagnostics tests.
The CMD ImPACT business planning tool is a simple software programme and is powered by a MS Excel-based program that has been created and refined in conjunction with NHS pathology laboratories.
Outside of the Excel spreadsheet, these analytics, visual charts and insights also feed directly into a pre-populated, tailored Word document.
This acts as an adaptable business case template for laboratories to apply for more diagnostics funding.
Alternatively, laboratories can enter the analysis into other business case formats and documents. The tool is intuitive and easy to use with little or no training needed. The software works across all NHS computers, including Office 2003.
Watch this tutorial video to see how the tool works:
CMD ImPACT Tools:
CMD ImPACT Business Case Template
CMD ImPACT Business Planning Tool
